Analytical Data
-
Gene name
EPGN
- Application
-
Alternative Names
EPGN；Epigen
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q6UW88
-
Expression Region
24-95aa
-
AA Sequence
AVTVTPPITA QQADNIEGPI ALKFSHLCLE DHNSYCINGA CAFHHELEKA ICRCFTGYTG ERCEHLTLTS YA
-
Molecular Weight
7.9 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
EPGN (epidermal growth factor-containing protein 1) is an important protein that has garnered significant attention in biomedical research due to its role in various cellular processes, particularly in the context of cancer and tissue repair. Initially identified for its involvement in the regulation of cell proliferation and differentiation, EPGN is encoded by the EPGN gene and is characterized by its structure, which contains multiple epidermal growth factor (EGF)-like motifs. These motifs are known to interact with EGF receptors, suggesting a possible mechanism through which EPGN exerts its biological functions. Studies have indicated that EPGN may play a pivotal role in modulating the tumor microenvironment and influencing tumorigenesis, making it a potential target for therapeutic intervention. Furthermore, research has shown that EPGN can promote the proliferation of certain cell types and facilitate wound healing processes, thereby raising interest in its potential applications in regenerative medicine. Understanding the molecular pathways regulated by EPGN, along with its interactions with other signaling molecules, is critical for elucidating its role in health and disease. This has led to a growing body of research aimed at characterizing EPGN as a recombinant protein, exploring its functional properties, and assessing its potential as a biomarker or therapeutic agent. The ongoing investigation of EPGN's mechanisms of action highlights its relevance in modern biomedical research, particularly in the development of targeted therapies for cancer and regenerative medicine strategies.
